<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="duarte-gal" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">duarte-gal</book-part-id>
      <title-group>
        <title>Duarte Variant Galactosemia</title>
        <alt-title alt-title-type="alt-title">Synonym: Duarte Galactosemia</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Fridovich-Keil</surname>
            <given-names>Judith L</given-names>
          </name>
          <degrees>PhD</degrees>
          <aff>Department of Human Genetics<break/>Emory University School of Medicine<break/>Atlanta, Georgia</aff>
          <email>jfridov@emory.edu</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gambello</surname>
            <given-names>Michael J</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <aff>Division of Medical Genetics<break/>Department of Human Genetics<break/>Emory University School of Medicine<break/>Atlanta, Georgia</aff>
          <email>mgambel@emory.edu</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Singh</surname>
            <given-names>Rani H</given-names>
          </name>
          <degrees>PhD, RD</degrees>
          <aff>Division of Medical Genetics<break/>Department of Human Genetics<break/>Emory University School of Medicine<break/>Atlanta, Georgia</aff>
          <email>rsingh@emory.edu</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sharer</surname>
            <given-names>J Daniel</given-names>
          </name>
          <degrees>PhD</degrees>
          <aff>Division of Medical Genetics<break/>Department of Human Genetics<break/>Emory University School of Medicine<break/>Atlanta, Georgia</aff>
          <email>jon.d.sharer@emory.edu</email>
        </contrib>
      </contrib-group>
      <pub-history>
        <date iso-8601-date="2014-12-04" date-type="created">
          <day>4</day>
          <month>12</month>
          <year>2014</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="duane" document-type="chapter">Duane Syndrome</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="miyoshi" document-type="chapter">Dysferlinopathy</related-object>
      <abstract id="duarte-gal.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Infants with Duarte variant galactosemia who are on breast milk or a lactose-containing formula are typically, but not always, asymptomatic. Abnormalities, such as jaundice, which may be seen in some infants, resolve rapidly when the baby is switched to a low-galactose formula. Many healthcare professionals believe that Duarte variant galactosemia does not result in clinical disease either with or without dietary intervention; however, there are also reports to the contrary and no adequately powered study either confirming or refuting this assumption has been reported. Because available data about the neurodevelopmental outcomes of children with Duarte variant galactosemia are conflicting, further studies are warranted to determine what long-term outcomes are and whether the dietary intake of galactose in the first year of life influences outcome. Premature ovarian insufficiency has not been reported for girls or women with Duarte variant galactosemia.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>Duarte variant galactosemia is diagnosed by a combination of biochemical and genetic testing. Specifically, erythrocyte galactose-1-phosphate uridylyltransferase (GALT) enzyme activity is typically 14%-25% of control activity, and <italic toggle="yes">GALT</italic> genotyping reveals the presence of one pathogenic <italic toggle="yes">GALT</italic> variant in the heterozygous state together with a Duarte (D<sub>2</sub>) <italic toggle="yes">GALT</italic> allelic variant in either the heterozygous or homozygous state.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Currently no agreement exists as to whether infants with Duarte variant galactosemia benefit from dietary galactose restriction during infancy and early childhood. Thus, healthcare providers or parents may choose either to restrict dietary galactose in the first year of life or not. When dietary galactose is restricted in infancy, it is recommended that the child undergo a galactose challenge around age one year followed by measurement of the erythrocyte galactose-1-phosphate level. If the level is within the normal range (&#x0003c;1.0 mg/dL), dietary restriction of galactose is generally discontinued. When dietary galactose is not restricted in infancy, some healthcare providers choose to check the erythrocyte galactose-1-phosphate level at age one year to assure that the level is approaching the normal range.</p>
          <p><italic toggle="yes">Surveillance:</italic> For infants on dietary restriction of galactose: if the erythrocyte galactose-1-phosphate level is &#x0003e;1.0 mg/dL following a galactose challenge at age one year, galactose restriction may be resumed. In this case, the galactose challenge and measurement of erythrocyte galactose-1-phosphate level may be repeated every 4-6 months until the erythrocyte galactose-1-phosphate level stabilizes at &#x0003c;1.0 mg/dL.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> Opinion varies as to whether avoidance of all sources of milk and dairy products until age one year is warranted.</p>
          <p><italic toggle="yes">Evaluation of relatives at risk:</italic> If families with one child with Duarte variant galactosemia wish to evaluate their other children for Duarte variant galactosemia, molecular genetic testing for the <italic toggle="yes">GALT</italic> variants identified in the family can be performed.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>Duarte variant galactosemia is inherited in an autosomal recessive manner. When one parent is heterozygous for the <italic toggle="yes">GALT</italic> D<sub>2</sub> allele and the other parent is heterozygous for a <italic toggle="yes">GALT</italic> pathogenic variant, each child has, at conception, a 25% chance of having Duarte variant galactosemia, a 25% chance of being an asymptomatic carrier of the D<sub>2</sub> allele, a 25% chance of being an asymptomatic carrier of a <italic toggle="yes">GALT</italic> pathogenic variant, and a 25% chance of being unaffected and not a carrier of either <italic toggle="yes">GALT</italic> variant. Carrier testing for at-risk relatives and prenatal testing for pregnancies at increased risk requires prior identification of the <italic toggle="yes">GALT</italic> variants in the family and determination of the parental origin of each allele. Requests for prenatal testing for conditions such as Duarte variant galactosemia are not common.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="duarte-gal.Diagnosis">
        <title>Diagnosis</title>
        <p>Duarte variant galactosemia is defined by a combination of the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>One <italic toggle="yes">GALT</italic> pathogenic variant present in the heterozygous state plus the <italic toggle="yes">GALT</italic> Duarte (D<sub>2</sub>) variant allele present in either the heterozygous or homozygous state</p>
          </list-item>
          <list-item>
            <p>Erythrocyte galactose-1-phosphate uridylyltransferase (GALT) enzyme activity that is typically 14%-25% of control activity</p>
          </list-item>
        </list>
        <sec id="duarte-gal.Suggestive_Findings">
          <title>Suggestive Findings</title>
          <p>Duarte variant galactosemia should be considered in infants with a positive newborn screening (NBS) result for galactosemia (especially those demonstrating elevated concentrations of galactose and galactose metabolites in blood following exposure to milk), but few if any clinical findings.</p>
        </sec>
        <sec id="duarte-gal.Follow_up_Testing">
          <title>Follow up Testing</title>
          <p>Quantitative testing of erythrocyte GALT enzyme activity is the first recommended approach for a positive NBS result for galactosemia. Testing of erythrocyte galactose-1-phosphate and/or urinary galactitol may also be useful.</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Erythrocyte galactose-1-phosphate uridylyltransferase (GALT)</bold>
<bold>enzyme activity</bold> that is typically 14%-25% of control activity is consistent with a diagnosis of Duarte variant galactosemia [<xref ref-type="bibr" rid="duarte-gal.REF.langley.1997.366">Langley et al 1997</xref>, <xref ref-type="bibr" rid="duarte-gal.REF.ficicioglu.2008.206">Ficicioglu et al 2008</xref>, <xref ref-type="bibr" rid="duarte-gal.REF.carney.2009.1624">Carney et al 2009</xref>, <xref ref-type="bibr" rid="duarte-gal.REF.walter.2014">Walter &#x00026; Fridovich-Keil 2014</xref>, <xref ref-type="bibr" rid="duarte-gal.REF.pyhtila.2015.79">Pyhtila et al 2015</xref>]. Note: (1) While all states in the US now include screening for classic galactosemia in the NBS panel, some states have adjusted the newborn screening GALT enzyme activity cut-off level to maximize the detection of classic and clinical variant galactosemia while minimizing false positives and the detection of infants with Duarte variant galactosemia [<xref ref-type="bibr" rid="duarte-gal.REF.pyhtila.2015.79">Pyhtila et al 2015</xref>]. In those states, a NBS result for galactosemia that is not flagged as &#x0201c;abnormal&#x0201d; may not be informative for Duarte variant galactosemia. (2) GALT is a labile enzyme; exposure of the sample to heat and humidity in storage or transit (as sometimes occurs in hot climates especially during the summer months) can result in artifactual loss of activity.</p>
            </list-item>
            <list-item>
              <p><bold>Erythrocyte galactose-1-phosphate (Gal-1P) concentration</bold> may range from high (&#x0003e;30 mg/dL) to completely normal (&#x0003c;1.0 mg/dL) depending on the infant&#x02019;s recent dietary exposure to breast milk or lactose-containing formula.</p>
              <list list-type="bullet">
                <list-item>
                  <p>Erythrocyte galactose-1-phosphate concentrations may exceed 30 mg/dL within the first few weeks of life; however, even in infants with Duarte variant galactosemia who are not treated with a lactose-restricted diet the concentration tends to normalize (&#x0003c;1.0 mg/dL) within the first year [<xref ref-type="bibr" rid="duarte-gal.REF.ficicioglu.2008.206">Ficicioglu et al 2008</xref>, <xref ref-type="bibr" rid="duarte-gal.REF.ficicioglu.2010.1177">Ficicioglu et al 2010</xref>, <xref ref-type="bibr" rid="duarte-gal.REF.pyhtila.2015.79">Pyhtila et al 2015</xref>].</p>
                </list-item>
                <list-item>
                  <p>Erythrocyte galactose-1-phosphate concentration in infants placed on a lactose-restricted diet normalizes rapidly, decreasing to an almost undetectable level within one month [<xref ref-type="bibr" rid="duarte-gal.REF.ficicioglu.2008.206">Ficicioglu et al 2008</xref>].</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p><bold>Urinary galactitol</bold> may be elevated, but not to the same extent seen in classic galactosemia. For example, the mean urinary galactitol level in a cohort of children with Duarte variant galactosemia on unrestricted (regular) diet at age one year was 46&#x000b1;14 mmol/mol creatinine [<xref ref-type="bibr" rid="duarte-gal.REF.ficicioglu.2008.206">Ficicioglu et al 2008</xref>], and in a cohort of children with Duarte variant galactosemia on unrestricted galactose (regular) diet at ages one to six years was 31.6 mmol/mol creatinine [<xref ref-type="bibr" rid="duarte-gal.REF.ficicioglu.2010.1177">Ficicioglu et al 2010</xref>]; mean urinary galactitol in controls was reported as 29&#x000b1;23 mmol/mol creatinine [<xref ref-type="bibr" rid="duarte-gal.REF.ficicioglu.2010.1177">Ficicioglu et al 2010</xref>].</p>
            </list-item>
          </list>
          <p>Click <inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="duarte-gal-historic_tests.pdf" content-type="local-data">here</inline-supplementary-material> (pdf) for information on testing of historic interest.</p>
        </sec>
        <sec id="duarte-gal.Establishing_the_Diagnosis">
          <title>Establishing the Diagnosis</title>
          <p>The diagnosis of Duarte variant galactosemia is established in a proband by a combination of: (1) erythrocyte GALT enzyme activity that is typically 14%-25% of control activity; and (2) molecular genetic test results that include a heterozygous pathogenic <italic toggle="yes">GALT</italic> variant and the Duarte (D<sub>2</sub>) <italic toggle="yes">GALT</italic> allelic variant in either the heterozygous or homozygous state.</p>
          <p><bold>Duarte variant (D<sub>2</sub>) allele.</bold> Five sequence changes in <italic toggle="yes">cis</italic> configuration are found on the Duarte variant (D<sub>2</sub>) allele.</p>
          <list list-type="bullet">
            <list-item>
              <p>Four of the sequence changes are noncoding nucleotide variants that are unique to the D<sub>2</sub> allele. Of primary importance is a 4-bp deletion in the <italic toggle="yes">GALT</italic> promoter region (<xref ref-type="table" rid="duarte-gal.T.galt_allelic_variants_assoc">c.-119_-116delGTCA</xref>) that is considered to cause diminished transcription [<xref ref-type="bibr" rid="duarte-gal.REF.koz_k.1999.576">Koz&#x000e1;k et al 1999</xref>, <xref ref-type="bibr" rid="duarte-gal.REF.elsas.2001.297">Elsas et al 2001</xref>, <xref ref-type="bibr" rid="duarte-gal.REF.trbusek.2001.117">Trbusek et al 2001</xref>, <xref ref-type="bibr" rid="duarte-gal.REF.carney.2009.1624">Carney et al 2009</xref>]. The three remaining variants unique to the D<sub>2</sub> allele are <xref ref-type="table" rid="duarte-gal.T.galt_allelic_variants_assoc">c.378-27G&#x0003e;C</xref>, <xref ref-type="table" rid="duarte-gal.T.galt_allelic_variants_assoc">c.508-24G&#x0003e;A</xref>, and <xref ref-type="table" rid="duarte-gal.T.galt_allelic_variants_assoc">c.507+62G&#x0003e;A</xref>.</p>
            </list-item>
            <list-item>
              <p>While the fifth sequence change, the missense variant <xref ref-type="table" rid="duarte-gal.T.galt_allelic_variants_assoc">c.940A&#x0003e;G</xref> (p.Asn314Asp, also called N314D), is always present on the D<sub>2</sub> allele, it also occurs on other functionally normal <italic toggle="yes">GALT</italic> alleles that are called either D<sub>1</sub> or Los Angeles (LA) alleles. [<xref ref-type="bibr" rid="duarte-gal.REF.bergren.1973.1">Bergren &#x00026; Donnell 1973</xref>, <xref ref-type="bibr" rid="duarte-gal.REF.podskarbi.1996.638">Podskarbi et al 1996</xref>, <xref ref-type="bibr" rid="duarte-gal.REF.langley.1997.366">Langley et al 1997</xref>, <xref ref-type="bibr" rid="duarte-gal.REF.carney.2009.1624">Carney et al 2009</xref>]. For more information see <xref ref-type="sec" rid="duarte-gal.Molecular_Genetics">Molecular Genetics</xref>.</p>
            </list-item>
          </list>
          <p><bold>Pathogenic allele.</bold> A <italic toggle="yes">GALT</italic> pathogenic variant is one that results in absent or barely detectable GALT enzyme activity when it occurs in the homozygous state or the compound heterozygous state with another pathogenic variant; the resulting phenotypes are classic or clinical variant galactosemia. Note: Sometimes these pathogenic <italic toggle="yes">GALT</italic> variants are referred to collectively as G alleles.</p>
          <p>Approaches to molecular genetic testing can include the following:</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Sequence analysis</bold> can detect the D<sub>2</sub>
<italic toggle="yes">GALT</italic> allele as well as most <italic toggle="yes">GALT</italic> pathogenic variants. If the D<sub>2</sub> variant is identified in a sample in which GALT enzyme activity is &#x02264;25%, but no <italic toggle="yes">GALT</italic> pathogenic variant is identified, deletion/duplication analysis should be considered.</p>
            </list-item>
            <list-item>
              <p><bold>Targeted analysis for pathogenic variants</bold> (i.e., use of defined panel [set] of <italic toggle="yes">GALT</italic> variants) would detect the D<sub>2</sub> allele assuming the sequence variants characteristic of the D<sub>2</sub> allele were included in the panel; however, targeted analysis for pathogenic variants may be less effective than sequence analysis in detecting a pathogenic <italic toggle="yes">GALT</italic> allele because of the high allelic heterogeneity in classic and clinical variant galactosemia and the limited number of pathogenic variants usually included in such a panel.</p>
            </list-item>
          </list>
          <table-wrap id="duarte-gal.T.summary_of_molecular_geneti" position="anchor" orientation="portrait">
            <label>Table 1. </label>
            <caption>
              <p>Summary of Molecular Genetic Testing Used in Duarte Variant Galactosemia</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_duarte-gal.T.summary_of_molecular_geneti_1_1_1_1" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_duarte-gal.T.summary_of_molecular_geneti_1_1_1_1">Gene&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_duarte-gal.T.summary_of_molecular_geneti_1_1_1_2" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_duarte-gal.T.summary_of_molecular_geneti_1_1_1_2">Test Method</th>
                  <th id="hd_h_duarte-gal.T.summary_of_molecular_geneti_1_1_1_3" valign="middle" colspan="2" align="left" scope="colgroup" rowspan="1">Proportion of Probands in Whom the Method Detects:</th>
                </tr>
                <tr>
                  <th headers="hd_h_duarte-gal.T.summary_of_molecular_geneti_1_1_1_3" id="hd_h_duarte-gal.T.summary_of_molecular_geneti_1_1_2_1" valign="middle" colspan="1" align="left" scope="colgroup" rowspan="1">The Duarte (D<sub>2</sub>) Variant</th>
                  <th headers="hd_h_duarte-gal.T.summary_of_molecular_geneti_1_1_1_3" id="hd_h_duarte-gal.T.summary_of_molecular_geneti_1_1_2_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">A Pathogenic Variant</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_duarte-gal.T.summary_of_molecular_geneti_1_1_1_1" rowspan="3" valign="middle" align="left" scope="row" colspan="1">
                    <italic toggle="yes">GALT</italic>
                  </td>
                  <td headers="hd_h_duarte-gal.T.summary_of_molecular_geneti_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Targeted analysis for pathogenic variants</td>
                  <td headers="hd_h_duarte-gal.T.summary_of_molecular_geneti_1_1_1_3 hd_h_duarte-gal.T.summary_of_molecular_geneti_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">100% for a panel that includes the D<sub>2</sub> allele&#x000a0;<sup>2</sup></td>
                  <td headers="hd_h_duarte-gal.T.summary_of_molecular_geneti_1_1_1_3 hd_h_duarte-gal.T.summary_of_molecular_geneti_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Varies by panel</td>
                </tr>
                <tr>
                  <td headers="hd_h_duarte-gal.T.summary_of_molecular_geneti_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Sequence analysis&#x000a0;<sup>3</sup></td>
                  <td headers="hd_h_duarte-gal.T.summary_of_molecular_geneti_1_1_1_3 hd_h_duarte-gal.T.summary_of_molecular_geneti_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">100%</td>
                  <td headers="hd_h_duarte-gal.T.summary_of_molecular_geneti_1_1_1_3 hd_h_duarte-gal.T.summary_of_molecular_geneti_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">&#x0003e;95%</td>
                </tr>
                <tr>
                  <td headers="hd_h_duarte-gal.T.summary_of_molecular_geneti_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Deletion/duplication analysis&#x000a0;<sup>4</sup></td>
                  <td headers="hd_h_duarte-gal.T.summary_of_molecular_geneti_1_1_1_3 hd_h_duarte-gal.T.summary_of_molecular_geneti_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">0&#x000a0;<sup>5</sup></td>
                  <td headers="hd_h_duarte-gal.T.summary_of_molecular_geneti_1_1_1_3 hd_h_duarte-gal.T.summary_of_molecular_geneti_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Estimated &#x0003c;1%&#x000a0;<sup>6</sup></td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="duarte-gal.TF.1.1">
                <label>1. </label>
                <p>See <related-object source-id="gene" document-id="duarte-gal" object-id="duarte-gal.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein. See <xref ref-type="sec" rid="duarte-gal.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants.</p>
              </fn>
              <fn id="duarte-gal.TF.1.2">
                <label>2. </label>
                <p>A panel detecting only N314D but not the non-coding 4bp deletion associated with the D<sub>2</sub> allele or L218L associated with the Los Angeles (D<sub>1</sub>) allele may not be able to distinguish between the D<sub>1</sub> and D<sub>2</sub> alleles, thus making interpretation of test results difficult.</p>
              </fn>
              <fn id="duarte-gal.TF.1.3">
                <label>3. </label>
                <p><italic toggle="yes">GALT</italic> sequence analysis detects the D<sub>2</sub> allele as well as other variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
              </fn>
              <fn id="duarte-gal.TF.1.4">
                <label>4. </label>
                <p>Testing that identifies exonic or whole-gene deletions/duplications not detectable by sequence analysis of the coding and flanking intronic regions of genomic DNA. Included in the variety of methods that may be used are: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and chromosomal microarray (CMA) that includes this gene/chromosome segment.</p>
              </fn>
              <fn id="duarte-gal.TF.1.5">
                <label>5. </label>
                <p>Deletion/duplication analysis will not identify the D<sub>2</sub> allele.</p>
              </fn>
              <fn id="duarte-gal.TF.1.6">
                <label>6. </label>
                <p>Exon and multiexon <italic toggle="yes">GALT</italic> deletions have been reported; while rare overall, such deletions may be common in specific populations. See <related-object source-id="gene" document-id="duarte-gal" object-id="duarte-gal.molgen.TA">Table A</related-object>, <bold>Locus Specific</bold>.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><bold>Interpretation of molecular genetic test results.</bold> Although rare, some individuals with Duarte variant galactosemia are homozygous for <xref ref-type="table" rid="duarte-gal.T.galt_allelic_variants_assoc">c.940A&#x0003e;G</xref> (p.Asn314Asp, also called N314D) and heterozygous for a pathogenic <italic toggle="yes">GALT</italic> variant, indicating that the pathogenic variant coexists in <italic toggle="yes">cis</italic> configuration with either a D<sub>2</sub> or D<sub>1</sub> allele.</p>
          <p>Also rarely, some individuals with classic galactosemia (who by definition have biallelic <italic toggle="yes">GALT</italic> pathogenic variants) may also have either a D<sub>2</sub> or D<sub>1</sub> allele in <italic toggle="yes">cis</italic> configuration with one or both pathogenic <italic toggle="yes">GALT</italic> variants.</p>
          <p>Therefore, demonstrating the presence of the D<sub>2</sub> variant, or any of the individual <italic toggle="yes">GALT</italic> sequence changes associated with the D<sub>2</sub> allele, such as <xref ref-type="table" rid="duarte-gal.T.galt_allelic_variants_assoc">c.940A&#x0003e;G</xref> (p.Asn314Asp, or N314D), does not confirm the diagnosis of Duarte variant galactosemia or rule out a diagnosis of classic galactosemia. The presence of <italic toggle="yes">GALT</italic> variants must always be interpreted in conjunction with GALT enzyme activity levels.</p>
          <p>Of note, the parents of a child with an identified D<sub>2</sub>
<italic toggle="yes">GALT</italic> variant allele and a <italic toggle="yes">GALT</italic> pathogenic variant allele can undergo molecular genetic testing themselves to determine whether each parent carries one variant, or whether both <italic toggle="yes">GALT</italic> variants are found in one parent while the other parent carries neither variant.</p>
          <list list-type="bullet">
            <list-item>
              <p>If each parent carries one variant found in the child, the D<sub>2</sub> and pathogenic <italic toggle="yes">GALT</italic> variants identified in the child are in <italic toggle="yes">trans</italic> configuration (on separate chromosomes) consistent with a diagnosis of Duarte variant galactosemia in the child.</p>
            </list-item>
            <list-item>
              <p>If one parent carries both the D<sub>2</sub> and pathogenic <italic toggle="yes">GALT</italic> variants identified in the child while the other parent carries neither, the D<sub>2</sub> and pathogenic <italic toggle="yes">GALT</italic> variants in the child are most likely in <italic toggle="yes">cis</italic> configuration (coexisting on the same chromosome) consistent with a diagnosis of galactosemia carrier rather than Duarte variant galactosemia in the child.</p>
            </list-item>
          </list>
        </sec>
      </sec>
      <sec id="duarte-gal.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <p>Infants with Duarte variant galactosemia who are on breast milk or a lactose-containing formula are typically asymptomatic. However, anecdotal patient reports suggest that some infants with Duarte variant galactosemia may experience jaundice or other acute manifestations that resolve following removal of milk from the diet [Author, personal observation].</p>
        <p>The etiology and prevalence of acute complications among neonates with Duarte variant galactosemia exposed to milk remains unknown.</p>
        <p>Many healthcare professionals believe that Duarte variant galactosemia does not result in clinical disease either with or without dietary intervention; however, some reports contradict that assertion [<xref ref-type="bibr" rid="duarte-gal.REF.powell.2009.874">Powell et al 2009</xref>; <xref ref-type="bibr" rid="duarte-gal.REF.lynch">Lynch et al, in press</xref>] and no adequately powered study to confirm or refute it has been published.</p>
        <sec id="duarte-gal.Clinical_Description">
          <title>Clinical Description</title>
          <p>The natural history of Duarte variant galactosemia is poorly understood because (1) some infants with presumed Duarte variant galactosemia are born in states where they are not identified by newborn screening, and (2) those born in states where they are identified and diagnosed are typically clinically well as babies and toddlers and are therefore discharged from follow up.</p>
          <p>Infants with Duarte variant galactosemia may remain apparently asymptomatic regardless of galactose exposure.</p>
          <p><bold>Neurodevelopment.</bold> A study of neurodevelopment in 28 toddlers and very young children with Duarte variant galactosemia (confirmed by GALT enzyme activity of ~12%-50% of controls and <italic toggle="yes">GALT</italic> molecular genetic test results consistent with Duarte variant galactosemia) suggested no significant developmental defects regardless of diet [<xref ref-type="bibr" rid="duarte-gal.REF.ficicioglu.2008.206">Ficicioglu et al 2008</xref>].</p>
          <p>In contrast, a study assessing developmental outcomes of older children with a diagnosis of Duarte variant galactosemia (also confirmed by GALT enzymatic activity and <italic toggle="yes">GALT</italic> molecular genetic test results) reported that by mid-elementary school these children were more than twice as likely as their peers to receive special educational services for speech and/or language [<xref ref-type="bibr" rid="duarte-gal.REF.powell.2009.874">Powell et al 2009</xref>], implying the possibility of relatively increased risk of developmental difficulties in this population.</p>
          <p>A pilot study involving direct developmental assessments of ten children with biochemically and molecularly determined Duarte variant galactosemia and five controls, all between ages six and11 years, also demonstrated some notable differences between children with Duarte variant galactosemia and controls in socio-emotional development, delayed recall, and auditory processing speed [<xref ref-type="bibr" rid="duarte-gal.REF.lynch">Lynch et al, in press</xref>].</p>
          <p>Thus, further studies are needed to define the long-term outcomes of older children with Duarte variant galactosemia and to determine if exposure to galactose in the first year of life modifies outcome [<xref ref-type="bibr" rid="duarte-gal.REF.fernhoff.2010.1045">Fernhoff 2010</xref>].</p>
          <p><bold>Ovarian function in females.</bold> A study of anti-m&#x000fc;llerian hormone in young girls with enzymatically and/or molecularly confirmed Duarte variant galactosemia demonstrated no evidence of premature ovarian insufficiency [<xref ref-type="bibr" rid="duarte-gal.REF.badik.2011.469">Badik et al 2011</xref>]. Further, family studies of newly diagnosed infants with classic or Duarte variant galactosemia sometimes reveal that the mother herself has Duarte variant galactosemia, confirming that women with Duarte variant galactosemia can be fertile and carry a pregnancy successfully to term.</p>
        </sec>
        <sec id="duarte-gal.GenotypePhenotype_Correlation">
          <title>Genotype-Phenotype Correlations</title>
          <p>By definition, all individuals with Duarte variant galactosemia have at least one D<sub>2</sub>
<italic toggle="yes">GALT</italic> allele (see <xref ref-type="sec" rid="duarte-gal.Molecular_Genetics">Molecular Genetics</xref>) and one pathogenic <italic toggle="yes">GALT</italic> allele in <italic toggle="yes">trans</italic> configuration; however, given the large number of known pathogenic <italic toggle="yes">GALT</italic> alleles, the pathogenic <italic toggle="yes">GALT</italic> allele is likely to differ between families with Duarte variant galactosemia. No significant genotype-phenotype relationships for Duarte variant galactosemia with regard to different pathogenic <italic toggle="yes">GALT</italic> alleles have been reported.</p>
        </sec>
        <sec id="duarte-gal.Nomenclature">
          <title>Nomenclature</title>
          <p>Duarte variant galactosemia may also be called Duarte galactosemia or DG.</p>
          <p>In some instances Duarte variant galactosemia has been called biochemical variant galactosemia.</p>
          <p>Sometimes, Duarte variant galactosemia is simply called variant galactosemia; however, this term is better reserved for individuals now said to have &#x02018;<related-object link-type="booklink" source-id="gene" document-id="galactosemia" document-type="chapter">clinical variant galactosemia</related-object>,&#x02019; who do not have a <italic toggle="yes">GALT</italic> D<sub>2</sub> allele but rather have biallelic <italic toggle="yes">GALT</italic> pathogenic variants that result in a low level of residual GALT enzyme activity. Of note, kinase deficiency and epimerase deficiency are also sometimes called &#x02018;variant&#x02019; galactosemia. Thus, unless the term Duarte, D, DG, or D<sub>2</sub> is explicit, the reader should not assume that the term variant galactosemia implies Duarte variant galactosemia.</p>
          <p>Pathogenic variants that completely or nearly abolish GALT enzyme activity are sometimes called G alleles. Individuals who have biallelic pathogenic variants have <related-object link-type="booklink" source-id="gene" document-id="galactosemia" document-type="chapter">classic or clinical variant galactosemia</related-object>.</p>
        </sec>
        <sec id="duarte-gal.Prevalence">
          <title>Prevalence</title>
          <p>The prevalence of Duarte variant galactosemia is difficult to confirm due to incomplete ascertainment. For example, while <related-object link-type="booklink" source-id="gene" document-id="galactosemia" document-type="chapter">classic galactosemia</related-object> is detected in close to 1:50,000 screened births in most states in the United States, Duarte variant galactosemia is detected in as many as 1:3,500 screened births in some states and essentially zero in others, largely reflecting differences in newborn screening protocols [<xref ref-type="bibr" rid="duarte-gal.REF.pyhtila.2015.79">Pyhtila et al 2015</xref>] (see <xref ref-type="sec" rid="duarte-gal.Diagnosis">Diagnosis</xref>, <bold>Erythrocyte galactose-1-phosphate uridylyltransferase (GALT) enzyme activity</bold>).</p>
          <p>The true prevalence of Duarte variant galactosemia in the US newborn population is believed to be approximately tenfold the prevalence of classic galactosemia [<xref ref-type="bibr" rid="duarte-gal.REF.fernhoff.2010.1045">Fernhoff 2010</xref>, <xref ref-type="bibr" rid="duarte-gal.REF.pyhtila.2015.79">Pyhtila et al 2015</xref>].</p>
          <p>Among newborns diagnosed with Duarte variant galactosemia some patterns implicating differential prevalence by race are evident [<xref ref-type="bibr" rid="duarte-gal.REF.pyhtila.2015.79">Pyhtila et al 2015</xref>]. For example, Duarte variant galactosemia is more common among infants of European ancestry and less prevalent among infants of African American or Asian ancestry. These differences parallel recognized differences among these populations in the prevalence of the D<sub>2</sub> variant and other known <italic toggle="yes">GALT</italic> pathogenic variants [<xref ref-type="bibr" rid="duarte-gal.REF.pyhtila.2015.79">Pyhtila et al 2015</xref>].</p>
        </sec>
      </sec>
      <sec id="duarte-gal.Genetically_Related_Allelic_D">
        <title>Genetically Related (Allelic) Disorders</title>
        <p><related-object link-type="booklink" source-id="gene" document-id="galactosemia" document-type="chapter">Classic galactosemia and clinical variant galactosemia</related-object> are the two phenotypes, other than Duarte variant galactosemia, associated with mutation of <italic toggle="yes">GALT.</italic> The genotypes that give rise to these phenotypes have two <italic toggle="yes">GALT</italic> pathogenic variants that result in either absent or barely detectable GALT enzyme activity.</p>
      </sec>
      <sec id="duarte-gal.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Most infants with Duarte variant galactosemia are diagnosed in the follow-up evaluation to a positive newborn screening result for galactosemia. The differential diagnosis of a positive newborn screen for galactosemia is:</p>
        <list list-type="bullet">
          <list-item>
            <p>
              <related-object link-type="booklink" source-id="gene" document-id="galactosemia" document-type="chapter">Classic galactosemia and clinical variant galactosemia</related-object>
            </p>
          </list-item>
          <list-item>
            <p>Duarte variant galactosemia</p>
          </list-item>
          <list-item>
            <p>
              <related-object link-type="booklink" source-id="gene" document-id="gale-def" document-type="chapter">GALE (epimerase) deficiency</related-object>
            </p>
          </list-item>
          <list-item>
            <p>GALK (galactokinase) deficiency</p>
          </list-item>
          <list-item>
            <p>A false positive result which includes:</p>
            <list list-type="bullet">
              <list-item>
                <p>Heterozygotes (carriers) for a <italic toggle="yes">GALT</italic> pathogenic variant;</p>
              </list-item>
              <list-item>
                <p>Other combinations of partially impaired <italic toggle="yes">GALT</italic> alleles (e.g., D<sub>2</sub> variant homozygotes);</p>
              </list-item>
              <list-item>
                <p>Individuals with completely normal GALT enzyme activity whose dried blood spot or markers of galactose metabolism were technically compromised for some reason.</p>
              </list-item>
            </list>
          </list-item>
        </list>
        <p><bold>Erythrocyte GALT enzyme activity.</bold> Measuring erythrocyte GALT enzyme activity is often the first step in differential diagnosis of a positive newborn screening result for galactosemia. Erythrocytes from individuals with classic galactosemia demonstrate very low to undetectable GALT enzyme activity.</p>
        <p>In contrast, GALT enzyme activity in erythrocytes from individuals:</p>
        <list list-type="bullet">
          <list-item>
            <p>With Duarte variant galactosemia is close to 14%-25% that of controls [<xref ref-type="bibr" rid="duarte-gal.REF.ficicioglu.2008.206">Ficicioglu et al 2008</xref>, <xref ref-type="bibr" rid="duarte-gal.REF.pyhtila.2015.79">Pyhtila et al 2015</xref>];</p>
          </list-item>
          <list-item>
            <p>Who are carriers of one pathogenic <italic toggle="yes">GALT</italic> allele or homozygous for the D<sub>2</sub> variant is close to 50% that of controls;</p>
          </list-item>
          <list-item>
            <p>Who are heterozygous for one D<sub>2</sub> variant (i.e., are carriers) is close to 75% that of controls;</p>
          </list-item>
          <list-item>
            <p>Who have <related-object link-type="booklink" source-id="gene" document-id="gale-def" document-type="chapter">GALE (epimerase) deficiency</related-object> or GALK (galactokinase) deficiency is indistinguishable from that of controls [<xref ref-type="bibr" rid="duarte-gal.REF.langley.1997.366">Langley et al 1997</xref>, <xref ref-type="bibr" rid="duarte-gal.REF.carney.2009.1624">Carney et al 2009</xref>, <xref ref-type="bibr" rid="duarte-gal.REF.pyhtila.2015.79">Pyhtila et al 2015</xref>].</p>
          </list-item>
        </list>
        <p><bold>Erythrocyte galactose-1-phosphate</bold> levels in infants with Duarte variant galactosemia exposed to galactose may be elevated. Although these erythrocyte galactose-1-phosphate levels overlap those seen in classic galactosemia, they typically do not exceed 30 mg/dL [<xref ref-type="bibr" rid="duarte-gal.REF.ficicioglu.2008.206">Ficicioglu et al 2008</xref>, <xref ref-type="bibr" rid="duarte-gal.REF.pyhtila.2015.79">Pyhtila et al 2015</xref>]. In contrast, in classic galactosemia levels &#x0003e;50 mg/dL are not uncommon, and in some samples erythrocyte galactose-1-phosphate exceeds 100 mg/dL [<xref ref-type="bibr" rid="duarte-gal.REF.walter.2014">Walter &#x00026; Fridovich-Keil 2014</xref>, <xref ref-type="bibr" rid="duarte-gal.REF.pyhtila.2015.79">Pyhtila et al 2015</xref>].</p>
      </sec>
      <sec id="duarte-gal.Management">
        <title>Management</title>
        <sec id="duarte-gal.Evaluations_Following_Initial">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs in an infant diagnosed with Duarte variant galactosemia, a clinical genetics consultation is recommended.</p>
        </sec>
        <sec id="duarte-gal.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>There is currently no uniform standard of care for patients with Duarte variant galactosemia. Agreement has not been reached as to whether individuals with Duarte variant galactosemia with residual erythrocyte GALT enzyme activity in the range of 14%-25% of controls should be restricted from galactose intake during infancy and early childhood. Until a sufficiently sensitive and statistically powerful study is conducted to determine whether galactose exposure negatively affects long-term developmental outcomes in children with Duarte variant galactosemia, the controversy concerning intervention and outcomes is likely to persist.</p>
          <p>Because it is unclear if acute or long-term manifestations can result from Duarte variant galactosemia, and if so, whether dietary galactose restriction would prevent or resolve the issues that have been reported [<xref ref-type="bibr" rid="duarte-gal.REF.powell.2009.874">Powell et al 2009</xref>, <xref ref-type="bibr" rid="duarte-gal.REF.lynch">Lynch et al, in press</xref>], any developmental or psychosocial problems experienced by a child with Duarte variant galactosemia should be treated symptomatically and the possibility of other causes should be explored.</p>
          <p><bold>Approach for non-treatment.</bold> Healthcare providers who choose not to treat infants with Duarte variant galactosemia by dietary restriction of galactose in the first year of life generally consider Duarte variant galactosemia to be of no clinical significance. These healthcare providers argue against the interruption of breastfeeding when there is no clear evidence to justify it [<xref ref-type="bibr" rid="duarte-gal.REF.fernhoff.2010.1045">Fernhoff 2010</xref>]. Of note, continued galactose-1-phosphate accumulation may be seen with lactose ingestion but is usually without overt sequelae.</p>
          <p>If the infant has not been placed on a galactose-restricted diet, or if feedings are alternating between breast milk and low galactose formula, it is reasonable to check the erythrocyte galactose-1-phosphate level by age 12 months (or sooner if an earlier erythrocyte galactose-1-phosphate level was particularly high) to ensure that the level is approaching control range by age 12 months.</p>
          <p><bold>Approach for treatment.</bold> Healthcare providers who choose to treat infants with Duarte variant galactosemia by dietary restriction of galactose in the first year of life generally consider the intervention to be potentially preventive rather than responsive to current disease manifestations. Options for dietary intervention [<xref ref-type="bibr" rid="duarte-gal.REF.fernhoff.2010.1045">Fernhoff 2010</xref>, <xref ref-type="bibr" rid="duarte-gal.REF.pyhtila.2015.79">Pyhtila et al 2015</xref>] include:</p>
          <list list-type="bullet">
            <list-item>
              <p>Full dietary restriction of galactose for all infants, through age one year, at which time a galactose challenge is performed;</p>
            </list-item>
            <list-item>
              <p>Following the recommendations for <related-object link-type="booklink" source-id="gene" document-id="galactosemia" document-type="chapter">clinical variant galactosemia</related-object>: immediate dietary galactose restriction for infants with erythrocyte galactose-1-phosphate &#x0003e;10 mg/dL;</p>
            </list-item>
            <list-item>
              <p>A compromise approach in which parents either alternate feeding breast milk with low galactose formula, or non-breastfeeding parents use low galactose formula rather than a milk-based formula.</p>
            </list-item>
          </list>
          <p><bold>The galactose challenge</bold>. If treatment is the chosen approach, conducting a galactose challenge at some point should be considered. For example:</p>
          <list list-type="bullet">
            <list-item>
              <p>Obtain a baseline erythrocyte galactose-1-phosphate level at diagnosis and again around age six months (i.e., after the introduction of solid foods).</p>
            </list-item>
            <list-item>
              <p>At age 12 months, gradually liberalize the dietary intake of galactose, and obtain an erythrocyte galactose-1-phosphate level one month later.</p>
            </list-item>
            <list-item>
              <p>If the erythrocyte galactose-1-phosphate level is within the normal range (&#x0003c;1.0 mg/dL) despite milk ingestion, dietary restriction of galactose is not resumed.</p>
            </list-item>
          </list>
        </sec>
        <sec id="duarte-gal.Surveillance">
          <title>Surveillance</title>
          <p>Most individuals diagnosed with Duarte variant galactosemia as infants who are followed by a genetics or metabolic specialist are discharged from follow up after a successful galactose challenge at age one year (see <xref ref-type="sec" rid="duarte-gal.Treatment_of_Manifestations">Treatment of Manifestations</xref>).</p>
          <p>Among children with Duarte variant galactosemia who have been restricted for dietary galactose as infants, if the erythrocyte galactose-1-phosphate level is &#x0003e;1.0 mg/dL following a galactose challenge at age one year, galactose restriction may be resumed, and the galactose challenge and measurement of erythrocyte galactose-1-phosphate level repeated every four to six months until the level can be stabilized at &#x0003c;1.0 mg/dL.</p>
        </sec>
        <sec id="duarte-gal.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>It is unclear if there are any agents or circumstances that individuals with Duarte variant galactosemia should avoid.</p>
          <p>Some healthcare providers recommend avoiding all sources of milk and dairy products until age one year as a precaution against possible galactose toxicity; other healthcare providers argue that this precaution is not warranted. See <xref ref-type="sec" rid="duarte-gal.Treatment_of_Manifestations">Treatment of Manifestations</xref>.</p>
        </sec>
        <sec id="duarte-gal.Evaluation_of_Relatives_at_Ri">
          <title>Evaluation of Relatives at Risk</title>
          <p>Some families with one child with Duarte variant galactosemia wish to evaluate their other children for Duarte variant galactosemia; however, it has not been established that avoidance of all sources of milk and dairy products is warranted in any siblings who test positive for Duarte variant galactosemia.</p>
          <p>If the <italic toggle="yes">GALT</italic> genotype of the proband is known, molecular genetic testing can be used to clarify the genetic status of at-risk sibs: sibs can be tested for the presence of the D<sub>2</sub> allele and the specific <italic toggle="yes">GALT</italic> pathogenic variant identified in the proband.</p>
          <p>See <xref ref-type="sec" rid="duarte-gal.Related_Genetic_Counseling_Is">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="duarte-gal.Pregnancy_Management">
          <title>Pregnancy Management</title>
          <p>There are no known additional risks associated with pregnancy for a woman with Duarte variant galactosemia or for a fetus with Duarte variant galactosemia.</p>
        </sec>
        <sec id="duarte-gal.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p>
        </sec>
      </sec>
      <sec id="duarte-gal.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="duarte-gal.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Duarte variant galactosemia is inherited in an autosomal recessive manner. Individuals with Duarte variant galactosemia have at least one Duarte (D<sub>2</sub>) variant <italic toggle="yes">GALT</italic> allele and one <italic toggle="yes">GALT</italic> pathogenic variant in <italic toggle="yes">trans</italic> configuration (on homologous chromosomes).</p>
        </sec>
        <sec id="duarte-gal.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Typically, one parent of a child with Duarte variant galactosemia carries the Duarte (D<sub>2</sub>) variant <italic toggle="yes">GALT</italic> allele and the other parent carries a <italic toggle="yes">GALT</italic> pathogenic variant. Molecular genetic testing is needed to clarify the genetic status of parents (see <xref ref-type="sec" rid="duarte-gal.Establishing_the_Diagnosis">Establishing the Diagnosis</xref>, <bold>Interpretation of molecular genetic test results</bold>).</p>
            </list-item>
            <list-item>
              <p>Rarely, a parent may have Duarte variant galactosemia or another genotype that includes the D<sub>2</sub> variant (e.g., homozygosity for the Duarte variant).</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) of a single <italic toggle="yes">GALT</italic> pathogenic variant in <italic toggle="yes">trans</italic> configuration with a normal <italic toggle="yes">GALT</italic> allele, or people who carry either one or two D<sub>2</sub> alleles are clinically asymptomatic and do not have Duarte variant galactosemia.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The risk to the sibs of the proband depends on the genetic status of the proband&#x02019;s parents.</p>
            </list-item>
            <list-item>
              <p>When one parent is heterozygous for the D<sub>2</sub> allele and the other parent is heterozygous for a <italic toggle="yes">GALT</italic> pathogenic variant each sib has at conception a:</p>
              <list list-type="bullet">
                <list-item>
                  <p>25% chance of having Duarte variant galactosemia;</p>
                </list-item>
                <list-item>
                  <p>25% chance of being an asymptomatic carrier of the D<sub>2</sub> allele;</p>
                </list-item>
                <list-item>
                  <p>25% chance of being an asymptomatic carrier of a <italic toggle="yes">GALT</italic> pathogenic variant;</p>
                </list-item>
                <list-item>
                  <p>25% chance of being unaffected and not a carrier of either variant.</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) of (1) a single <italic toggle="yes">GALT</italic> pathogenic variant in <italic toggle="yes">trans</italic> configuration with a normal <italic toggle="yes">GALT</italic> allele or (2) either one or two D<sub>2</sub>
<italic toggle="yes">GALT</italic> alleles are clinically asymptomatic and do not have Duarte variant galactosemia.</p>
            </list-item>
            <list-item>
              <p>Risks to sibs are different for other parental genotypes. Referral for genetic counseling is indicated for such families. Note: In some families, it is possible for the sibs of a proband with Duarte variant galactosemia to have <related-object link-type="booklink" source-id="gene" document-id="galactosemia" document-type="chapter">classic or clinical variant galactosemia</related-object> depending on the genetic status of the proband&#x02019;s parents. For example, if one parent has Duarte variant galactosemia and the other parent is a carrier for a pathogenic <italic toggle="yes">GALT</italic> variant, each sib has a 25% chance of having classic or clinical variant galactosemia.</p>
            </list-item>
          </list>
          <p>
            <bold>Offspring of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Each child of an individual with Duarte variant galactosemia is typically an obligate heterozygote (carrier) of a <italic toggle="yes">GALT</italic> variant allele (i.e., either a <italic toggle="yes">GALT</italic> pathogenic variant or the D<sub>2</sub> allele).</p>
            </list-item>
            <list-item>
              <p>Accurate determination of the risk to offspring is only possible after molecular genetic testing of the proband's reproductive partner.</p>
            </list-item>
          </list>
          <p><bold>Other family members.</bold> Each sib of the proband&#x02019;s parents is at a 50% risk of being a carrier; typically, one side of the family will be at increased risk of carrying a D<sub>2</sub>
<italic toggle="yes">GALT</italic> allele while the other side of the family will be at increased risk of carrying a <italic toggle="yes">GALT</italic> pathogenic variant.</p>
        </sec>
        <sec id="duarte-gal.Carrier_Detection">
          <title>Carrier Detection</title>
          <p>Carrier testing for at-risk relatives requires prior identification of the <italic toggle="yes">GALT</italic> variants in the family and determination of the parental origin of each allele.</p>
        </sec>
        <sec id="duarte-gal.Related_Genetic_Counseling_Is">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="duarte-gal.Evaluation_of_Relatives_at_Ri">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of available prenatal testing options is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who have Duarte variant galactosemia, are carriers, or are at risk of being carriers.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="duarte-gal.Prenatal_Testing">
          <title>Prenatal Testing</title>
          <p>If the <italic toggle="yes">GALT</italic> variants have been identified in an affected family member, prenatal testing for pregnancies at increased risk may be available from a clinical laboratory that offers either testing for this disease/gene or custom prenatal testing.</p>
          <p>Requests for prenatal testing for conditions such as Duarte variant galactosemia are not common. Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although most centers would consider decisions about prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p>
          <p><bold>Preimplantation genetic diagnosis (PGD)</bold> may be an option for some families in which the <italic toggle="yes">GALT</italic> variants have been identified.</p>
        </sec>
      </sec>
      <sec id="duarte-gal.Resources">
        <title>Resources</title>
      </sec>
      <sec id="duarte-gal.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <sec id="duarte-gal.Molecular_Genetic_Pathogenesi">
          <title>Molecular Genetic Pathogenesis</title>
          <p>The mechanism of pathogenesis of the <italic toggle="yes">GALT</italic> D<sub>2</sub> allele was a point of some confusion in the past [<xref ref-type="bibr" rid="duarte-gal.REF.elsas.1994.1030">Elsas et al 1994</xref>, <xref ref-type="bibr" rid="duarte-gal.REF.fridovichkeil.1995.121">Fridovich-Keil et al 1995</xref>, <xref ref-type="bibr" rid="duarte-gal.REF.podskarbi.1996.638">Podskarbi et al 1996</xref>, <xref ref-type="bibr" rid="duarte-gal.REF.langley.1997.366">Langley et al 1997</xref>, <xref ref-type="bibr" rid="duarte-gal.REF.lai.1998.28">Lai et al 1998</xref>, <xref ref-type="bibr" rid="duarte-gal.REF.koz_k.1999.576">Koz&#x000e1;k et al 1999</xref>, <xref ref-type="bibr" rid="duarte-gal.REF.elsas.2001.297">Elsas et al 2001</xref>, <xref ref-type="bibr" rid="duarte-gal.REF.carney.2009.1624">Carney et al 2009</xref>], likely reflecting the complex nature of the allele and the fact that the linked 4-bp promoter deletion (c.-119_-116delGTCA) was not initially recognized. The consensus is now that this 4-bp promoter deletion is actually the causal variant, leading to slight impairment of expression of what is a fully functional GALT protein.</p>
          <p>The mechanism of pathogenesis of different <italic toggle="yes">GALT</italic> pathogenic variants as a cause of classic / clinical variant galactosemia is described in <related-object link-type="booklink" source-id="gene" document-id="galactosemia" document-type="chapter">Classic Galactosemia and Clinical Variant Galactosemia</related-object>.</p>
          <p><bold>Gene structure.</bold> See <related-object link-type="booklink" source-id="gene" document-id="galactosemia" document-type="chapter">Classic Galactosemia and Clinical Variant Galactosemia</related-object> for information about <italic toggle="yes">GALT</italic>. See also <related-object source-id="gene" document-id="duarte-gal" object-id="duarte-gal.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
          <p>
            <bold>Benign allelic variants</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Duarte variant (D<sub>2</sub>) allele.</bold> Some consider the D<sub>2</sub> variant allele itself to be benign. Five sequence changes in <italic toggle="yes">cis</italic> configuration are found on the D<sub>2</sub> allele. Four are noncoding nucleotide variants that are unique to the D<sub>2</sub> allele.</p>
              <list list-type="bullet">
                <list-item>
                  <p>Of primary importance is a 4-bp deletion in the <italic toggle="yes">GALT</italic> promoter region (c.-119_-116delGTCA) that slightly impairs gene expression [<xref ref-type="bibr" rid="duarte-gal.REF.koz_k.1999.576">Koz&#x000e1;k et al 1999</xref>, <xref ref-type="bibr" rid="duarte-gal.REF.elsas.2001.297">Elsas et al 2001</xref>, <xref ref-type="bibr" rid="duarte-gal.REF.trbusek.2001.117">Trbusek et al 2001</xref>, <xref ref-type="bibr" rid="duarte-gal.REF.carney.2009.1624">Carney et al 2009</xref>].</p>
                </list-item>
                <list-item>
                  <p>The three remaining variants unique to D<sub>2</sub> are c.378-27G&#x0003e;C, c.508-24G&#x0003e;A, and c.507+62G&#x0003e;A.</p>
                </list-item>
                <list-item>
                  <p>The fifth sequence change is the missense variant c.940A&#x0003e;G (p.Asn314Asp, also called N314D); while always on the D<sub>2</sub> allele, c.940A&#x0003e;G also occurs on other functionally normal <italic toggle="yes">GALT</italic> alleles [<xref ref-type="bibr" rid="duarte-gal.REF.bergren.1973.1">Bergren &#x00026; Donnell 1973</xref>, <xref ref-type="bibr" rid="duarte-gal.REF.podskarbi.1996.638">Podskarbi et al 1996</xref>, <xref ref-type="bibr" rid="duarte-gal.REF.langley.1997.366">Langley et al 1997</xref>, <xref ref-type="bibr" rid="duarte-gal.REF.carney.2009.1624">Carney et al 2009</xref>].</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p><bold>Los Angeles (or D<sub>1</sub>) variant allele</bold> results in no diminution of GALT enzyme activity and is considered benign. Note: The Los Angeles (LA) <italic toggle="yes">GALT</italic> variant (D<sub>1</sub>) has the identical c.940A&#x0003e;G missense variant as the D<sub>2</sub> variant but does not have the c.-119_-116delGTCA promoter deletion. Instead, it is in <italic toggle="yes">cis</italic> configuration with the silent variant c.652C&#x0003e;T (p.Leu218Leu, also called L218L). See <related-object link-type="booklink" source-id="gene" document-id="galactosemia" document-type="chapter">Classic Galactosemia and Clinical Variant Galactosemia</related-object>. The D<sub>1</sub> variant allele does not cause galactosemia and is associated with normal or slightly increased erythrocyte GALT enzyme activity [<xref ref-type="bibr" rid="duarte-gal.REF.langley.1997.366">Langley et al 1997</xref>, <xref ref-type="bibr" rid="duarte-gal.REF.elsas.2001.297">Elsas et al 2001</xref>].</p>
            </list-item>
          </list>
          <table-wrap id="duarte-gal.T.galt_allelic_variants_assoc" position="anchor" orientation="portrait">
            <label>Table 2. </label>
            <caption>
              <p><italic toggle="yes">GALT</italic> Allelic Variants Associated with the D<sub>2</sub> Allele Discussed in This <italic toggle="yes">GeneReview</italic></p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_duarte-gal.T.galt_allelic_variants_assoc_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change<break/>(Alias&#x000a0;<sup>1</sup>)</th>
                  <th id="hd_h_duarte-gal.T.galt_allelic_variants_assoc_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change</th>
                  <th id="hd_h_duarte-gal.T.galt_allelic_variants_assoc_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_duarte-gal.T.galt_allelic_variants_assoc_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.-119_-116delGTCA</td>
                  <td headers="hd_h_duarte-gal.T.galt_allelic_variants_assoc_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">NA (reduces promoter function)</td>
                  <td headers="hd_h_duarte-gal.T.galt_allelic_variants_assoc_1_1_1_3" rowspan="5" valign="middle" align="left" colspan="1">
                    <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nucleotide/22165415">NM_000155.2</ext-link>
                    <break/>
                    <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/22165416">NP_000146.2</ext-link>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_duarte-gal.T.galt_allelic_variants_assoc_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.940A&#x0003e;G</td>
                  <td headers="hd_h_duarte-gal.T.galt_allelic_variants_assoc_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Asn314Asp (N314D)</td>
                </tr>
                <tr>
                  <td headers="hd_h_duarte-gal.T.galt_allelic_variants_assoc_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.378-27G&#x0003e;C<break/>(IVS4-27G&#x0003e;C)</td>
                  <td headers="hd_h_duarte-gal.T.galt_allelic_variants_assoc_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">NA</td>
                </tr>
                <tr>
                  <td headers="hd_h_duarte-gal.T.galt_allelic_variants_assoc_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.508-24G&#x0003e;A<break/>(IVS5-24G&#x0003e;A)</td>
                  <td headers="hd_h_duarte-gal.T.galt_allelic_variants_assoc_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">NA</td>
                </tr>
                <tr>
                  <td headers="hd_h_duarte-gal.T.galt_allelic_variants_assoc_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.507+62G&#x0003e;A<break/>(IVS5-62G&#x0003e;A)</td>
                  <td headers="hd_h_duarte-gal.T.galt_allelic_variants_assoc_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">NA</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
              </fn>
              <fn>
                <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
              </fn>
              <fn id="duarte-gal.TF.2.1">
                <label>1. </label>
                <p>Variant designation that does not conform to current naming conventions</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><bold>Pathogenic allelic variants.</bold> See <related-object link-type="booklink" source-id="gene" document-id="galactosemia" document-type="chapter">Classic Galactosemia and Clinical Variant Galactosemia</related-object> for information on other <italic toggle="yes">GALT</italic> alleles.</p>
          <p><bold>Normal gene product.</bold> The normal human GALT protein contains 379 amino acids and functions as a homodimer with two active sites [<xref ref-type="bibr" rid="duarte-gal.REF.wedekind.1995.11049">Wedekind et al 1995</xref>, <xref ref-type="bibr" rid="duarte-gal.REF.holden.2003.43885">Holden et al 2003</xref>].</p>
          <p>A <italic toggle="yes">GALT</italic> allele with only the c.940A&#x0003e;G (p.Asn314Asp) variant is thought to produce a fully functional protein [<xref ref-type="bibr" rid="duarte-gal.REF.andersen.1984.287">Andersen et al 1984</xref>, <xref ref-type="bibr" rid="duarte-gal.REF.fridovichkeil.1995.121">Fridovich-Keil et al 1995</xref>, <xref ref-type="bibr" rid="duarte-gal.REF.carney.2009.1624">Carney et al 2009</xref>].</p>
          <p><bold>Abnormal gene product.</bold> Abnormal gene products associated with different pathogenic alleles of <italic toggle="yes">GALT</italic> are described in <related-object link-type="booklink" source-id="gene" document-id="galactosemia" document-type="chapter">Classic Galactosemia and Clinical Variant Galactosemia</related-object>.</p>
        </sec>
      </sec>
      <sec id="duarte-gal.References">
        <title>References</title>
        <sec id="duarte-gal.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="duarte-gal.Literature_Cited.reflist0">
            <ref id="duarte-gal.REF.andersen.1984.287">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Andersen</surname>
                    <given-names>MW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Williams</surname>
                    <given-names>VP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sparkes</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sparkes</surname>
                    <given-names>RS</given-names>
                  </name>
                </person-group>
                <article-title>Transferase-deficiency galactosemia: Immunochemical studies of the Duarte and Los Angeles variants.</article-title>
                <source>Hum Genet.</source>
                <year>1984</year>
                <volume>65</volume>
                <fpage>287</fpage>
                <lpage>90</lpage>
                <pub-id pub-id-type="pmid">6321325</pub-id>
              </element-citation>
            </ref>
            <ref id="duarte-gal.REF.badik.2011.469">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Badik</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Casta&#x000f1;eda</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gleason</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spencer</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Epstein</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ficicioglu</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fitzgerald</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fridovich-Keil</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <article-title>Ovarian function in Duarte galactosemia.</article-title>
                <source>Fertil Steril.</source>
                <year>2011</year>
                <volume>96</volume>
                <fpage>469</fpage>
                <lpage>73.e1</lpage>
                <pub-id pub-id-type="pmid">21719007</pub-id>
              </element-citation>
            </ref>
            <ref id="duarte-gal.REF.bergren.1973.1">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bergren</surname>
                    <given-names>WG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Donnell</surname>
                    <given-names>GN</given-names>
                  </name>
                </person-group>
                <article-title>A new variant of galactose-1-phosphate uridyltransferase in man: the Los Angeles variant.</article-title>
                <source>Ann Hum Genet.</source>
                <year>1973</year>
                <volume>37</volume>
                <fpage>1</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">4759900</pub-id>
              </element-citation>
            </ref>
            <ref id="duarte-gal.REF.carney.2009.1624">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Carney</surname>
                    <given-names>AE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sanders</surname>
                    <given-names>RD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garza</surname>
                    <given-names>KR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McGaha</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bean</surname>
                    <given-names>LJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coffee</surname>
                    <given-names>BW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thomas</surname>
                    <given-names>JW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cutler</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kurtkaya</surname>
                    <given-names>NL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fridovich-Keil</surname>
                    <given-names>JL</given-names>
                  </name>
                </person-group>
                <article-title>Origins, distribution and expression of the Duarte-2 (D2) allele of galactose-1-phosphate uridylyltransferase.</article-title>
                <source>Hum Mol Genet.</source>
                <year>2009</year>
                <volume>18</volume>
                <fpage>1624</fpage>
                <lpage>32</lpage>
                <pub-id pub-id-type="pmid">19224951</pub-id>
              </element-citation>
            </ref>
            <ref id="duarte-gal.REF.elsas.1994.1030">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Elsas</surname>
                    <given-names>LJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dembure</surname>
                    <given-names>PP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Langley</surname>
                    <given-names>SD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paulk</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hjelm</surname>
                    <given-names>LN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fridovich-Keil</surname>
                    <given-names>JL</given-names>
                  </name>
                </person-group>
                <article-title>A common mutation associated with the Duarte Galactosemia allele.</article-title>
                <source>Am J Hum Genet.</source>
                <year>1994</year>
                <volume>54</volume>
                <fpage>1030</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">8198125</pub-id>
              </element-citation>
            </ref>
            <ref id="duarte-gal.REF.elsas.2001.297">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Elsas</surname>
                    <given-names>LJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lai</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saunders</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Langley</surname>
                    <given-names>SD</given-names>
                  </name>
                </person-group>
                <article-title>Functional analysis of the human galactose-1-phosphate uridyltransferase promoter in Duarte and LA variant galactosemia.</article-title>
                <source>Mol Genet Metab.</source>
                <year>2001</year>
                <volume>72</volume>
                <fpage>297</fpage>
                <lpage>305</lpage>
                <pub-id pub-id-type="pmid">11286503</pub-id>
              </element-citation>
            </ref>
            <ref id="duarte-gal.REF.fernhoff.2010.1045">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fernhoff</surname>
                    <given-names>PM</given-names>
                  </name>
                </person-group>
                <article-title>Duarte galactosemia: how sweet is it?</article-title>
                <source>Clin Chem.</source>
                <year>2010</year>
                <volume>56</volume>
                <fpage>1045</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">20489130</pub-id>
              </element-citation>
            </ref>
            <ref id="duarte-gal.REF.ficicioglu.2010.1177">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ficicioglu</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hussa</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gallagher</surname>
                    <given-names>PR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thomas</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yager</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>Monitoring of biochemical status in children with Duarte galactosemia: utility of galactose, galactitol, galactonate, and galactose 1-phosphate.</article-title>
                <source>Clin Chem.</source>
                <year>2010</year>
                <volume>56</volume>
                <fpage>1177</fpage>
                <lpage>82</lpage>
                <pub-id pub-id-type="pmid">20489133</pub-id>
              </element-citation>
            </ref>
            <ref id="duarte-gal.REF.ficicioglu.2008.206">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ficicioglu</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thomas</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yager</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gallagher</surname>
                    <given-names>PR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hussa</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mattie</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Day-Salvatore</surname>
                    <given-names>DL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Forbes</surname>
                    <given-names>BJ</given-names>
                  </name>
                </person-group>
                <article-title>Duarte (DG) galactosemia: a pilot study of biochemical and neurodevelopmental assessment in children detected by newborn screening.</article-title>
                <source>Mol Genet Metab.</source>
                <year>2008</year>
                <volume>95</volume>
                <fpage>206</fpage>
                <lpage>12</lpage>
                <pub-id pub-id-type="pmid">18976948</pub-id>
              </element-citation>
            </ref>
            <ref id="duarte-gal.REF.fridovichkeil.1995.121">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fridovich-Keil</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Quimby</surname>
                    <given-names>BB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wells</surname>
                    <given-names>L.</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mazur</surname>
                    <given-names>L. A.</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elsevier</surname>
                    <given-names>J. P.</given-names>
                  </name>
                </person-group>
                <article-title>Characterization of the N314D allele of human galactose-1-phosphate uridylyltransferase using a yeast expression system.</article-title>
                <source>Biochem Mol Med.</source>
                <year>1995</year>
                <volume>56</volume>
                <fpage>121</fpage>
                <lpage>30</lpage>
                <pub-id pub-id-type="pmid">8825075</pub-id>
              </element-citation>
            </ref>
            <ref id="duarte-gal.REF.holden.2003.43885">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Holden</surname>
                    <given-names>HM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rayment</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thoden</surname>
                    <given-names>JB</given-names>
                  </name>
                </person-group>
                <article-title>Structure and function of enzymes of the Leloir pathway for galactose metabolism.</article-title>
                <source>J Biol Chem.</source>
                <year>2003</year>
                <volume>278</volume>
                <fpage>43885</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">12923184</pub-id>
              </element-citation>
            </ref>
            <ref id="duarte-gal.REF.koz_k.1999.576">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Koz&#x000e1;k</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Francov&#x000e1;</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pij&#x000e1;ckov&#x000e1;</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Macku</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stastn&#x000e1;</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peskovov&#x000e1;</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martincov&#x000e1;</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krijt</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <article-title>Presence of a deletion in the 5' upstream region of the GALT gene in Duarte (D2) alleles.</article-title>
                <source>J Med Genet.</source>
                <year>1999</year>
                <volume>36</volume>
                <fpage>576</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">10424825</pub-id>
              </element-citation>
            </ref>
            <ref id="duarte-gal.REF.lai.1998.28">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lai</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Langley</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dembure</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hjelm</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elsas</surname>
                    <given-names>LI</given-names>
                  </name>
                </person-group>
                <article-title>The Duarte allele impairs biostability of galactose-1-phosphate uridyltransferase in human lymphoblasts.</article-title>
                <source>Hum Mutat.</source>
                <year>1998</year>
                <volume>11</volume>
                <fpage>28</fpage>
                <lpage>38</lpage>
                <pub-id pub-id-type="pmid">9450900</pub-id>
              </element-citation>
            </ref>
            <ref id="duarte-gal.REF.langley.1997.366">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Langley</surname>
                    <given-names>SD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lai</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dembure</surname>
                    <given-names>PP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hjelm</surname>
                    <given-names>LN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elsas</surname>
                    <given-names>LJ</given-names>
                  </name>
                </person-group>
                <article-title>Molecular Basis for Duarte and Los Angeles Variant Galactosemia.</article-title>
                <source>Am J Hum Genet.</source>
                <year>1997</year>
                <volume>60</volume>
                <fpage>366</fpage>
                <lpage>72</lpage>
                <pub-id pub-id-type="pmid">9012409</pub-id>
              </element-citation>
            </ref>
            <ref id="duarte-gal.REF.lynch">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lynch</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Potter</surname>
                    <given-names>NL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coles</surname>
                    <given-names>CD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fridovich-Keil</surname>
                    <given-names>JL</given-names>
                  </name>
                </person-group>
                <comment>in press</comment>
                <article-title>Developmental outcomes of school-age children with Duarte galactosemia: a pilot study.</article-title>
                <source>JIMD Rep.</source>
                <pub-id pub-id-type="pmid">25681083</pub-id>
              </element-citation>
            </ref>
            <ref id="duarte-gal.REF.podskarbi.1996.638">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Podskarbi</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kohlmetz</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gathof</surname>
                    <given-names>BS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kleinlein</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bieger</surname>
                    <given-names>WP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gresser</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shin</surname>
                    <given-names>YS</given-names>
                  </name>
                </person-group>
                <article-title>Molecular characterization of Duarte-1 and Duarte-2 variants of galactose-1-phosphate uridyltransferase.</article-title>
                <source>J Inherit Metab Dis.</source>
                <year>1996</year>
                <volume>19</volume>
                <fpage>638</fpage>
                <lpage>44</lpage>
                <pub-id pub-id-type="pmid">8892021</pub-id>
              </element-citation>
            </ref>
            <ref id="duarte-gal.REF.powell.2009.874">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Powell</surname>
                    <given-names>KK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Naarden Braun</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Singh</surname>
                    <given-names>RH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shapira</surname>
                    <given-names>SK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olney</surname>
                    <given-names>RS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yeargin-Allsopp</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Long-term speech and language developmental issues among children with Duarte galactosemia.</article-title>
                <source>Genet Med.</source>
                <year>2009</year>
                <volume>11</volume>
                <fpage>874</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">19904210</pub-id>
              </element-citation>
            </ref>
            <ref id="duarte-gal.REF.pyhtila.2015.79">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pyhtila</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shaw</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Neumann</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fridovich-Keil</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <article-title>Newborn screening for galactosemia in the United States: looking back, looking around, and looking ahead.</article-title>
                <source>JIMD Rep.</source>
                <year>2015</year>
                <volume>15</volume>
                <fpage>79</fpage>
                <lpage>93</lpage>
                <pub-id pub-id-type="pmid">24718839</pub-id>
              </element-citation>
            </ref>
            <ref id="duarte-gal.REF.trbusek.2001.117">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Trbusek</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Francova</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koz&#x000e1;k</surname>
                    <given-names>L</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Galactosemia: deletion in the 5&#x02019; upstream region of the GALT gene reduces promoter efficiency.</article-title>
                <source>Hum Genet.</source>
                <volume>109</volume>
                <fpage>117</fpage>
                <lpage>20</lpage>
                <pub-id pub-id-type="pmid">11479743</pub-id>
              </element-citation>
            </ref>
            <ref id="duarte-gal.REF.walter.2014">
              <mixed-citation publication-type="webpage">Walter JH, Fridovich-Keil JL. Galactosemia. In: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, Gibson K, Mitchell G, eds. <italic toggle="yes">The Online Metabolic and Molecular Bases of Inherited Disease (OMMBID)</italic>. Chap 72. New York, NY: McGraw-Hill. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://ommbid.mhmedical.com/">online</ext-link>. 2014. Accessed 5-2-16.</mixed-citation>
            </ref>
            <ref id="duarte-gal.REF.wedekind.1995.11049">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wedekind</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frey</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rayment</surname>
                    <given-names>I</given-names>
                  </name>
                </person-group>
                <article-title>Three-Dimensional Structure of Galactose-1-phosphate Uridylyltransferase from <italic toggle="yes">Escherichia coli</italic> at 1.8A Resolution.</article-title>
                <source>Biochemistry.</source>
                <year>1995</year>
                <volume>34</volume>
                <fpage>11049</fpage>
                <lpage>61</lpage>
                <pub-id pub-id-type="pmid">7669762</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="duarte-gal.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="duarte-gal.Acknowledgments">
          <title>Acknowledgments</title>
          <p>The authors are grateful to their colleagues and to the many families impacted by Duarte variant galactosemia who participate in research studies so that, working together, we will learn more about intervention and outcomes in this disorder.</p>
        </sec>
        <sec id="duarte-gal.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>4 December 2014 (me) Review posted live</p>
            </list-item>
            <list-item>
              <p>20 May 2014 (jfk) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
